Report cover image

Anticonvulsants Market by Drug types (AMPA, Barbiturate, Benzodiazepine), Indication (Anxiety, Bipolar Disorder, Borderline Personality Disorder) - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 192 Pages
SKU # IRE18417871

Description

Anticonvulsants Market by Drug types (AMPA, Barbiturate, Benzodiazepine), Indication (Anxiety, Bipolar Disorder, Borderline Personality Disorder) - Global Forecast 2024-2030


The Anticonvulsants Market size was estimated at USD 12.03 billion in 2023 and expected to reach USD 13.07 billion in 2024, at a CAGR 8.71% to reach USD 21.59 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Anticonvulsants Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anticonvulsants Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Anticonvulsants Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astrazeneca PLC, Bausch Health Companies Inc., Biocon Limited, Cadila Pharmaceuticals Limited, Cipla, Inc., Dr. Reddy's Laboratories Limited, Eisai Co., Ltd., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Jazz Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Lifecare Neuro Products Limited, Lundbeck A/S, Mankind Pharma Ltd., Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi S.A., Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Wockhardt Limited.

Market Segmentation & Coverage

This research report categorizes the Anticonvulsants Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug types

AMPA
  • Barbiturate
  • Benzodiazepine
  • Carbamate Anticonvulsants
  • Carbonic Anhydrase Inhibitor
  • Dibenzazepine
  • Triazine
  • Indication

    Anxiety
  • Bipolar Disorder
  • Borderline Personality Disorder
  • Epilepsy
  • Fibromyalgia
  • Migraine
  • Neuropathic Pain
  • Region

    Americas

    Argentina
  • Brazil
  • Canada
  • Mexico
  • United States

    California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas
  • Asia-Pacific

    Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam
  • Europe, Middle East & Africa

    Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom
    The report offers valuable insights on the following aspects:

    1. Market Penetration: It presents comprehensive information on the market provided by key players.
    2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
    3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
    4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
    5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
    The report addresses key questions such as:

    1. What is the market size and forecast of the Anticonvulsants Market?
    2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anticonvulsants Market?
    3. What are the technology trends and regulatory frameworks in the Anticonvulsants Market?
    4. What is the market share of the leading vendors in the Anticonvulsants Market?
    5. Which modes and strategic moves are suitable for entering the Anticonvulsants Market?


    Note: PDF & Excel + Online Access - 1 Year

    • Table of Contents

    192 Pages
    1. Preface
    1.1. Objectives of the Study
    1.2. Market Segmentation & Coverage
    1.3. Years Considered for the Study
    1.4. Currency & Pricing
    1.5. Language
    1.6. Limitations
    1.7. Assumptions
    1.8. Stakeholders
    2. Research Methodology
    2.1. Define: Research Objective
    2.2. Determine: Research Design
    2.3. Prepare: Research Instrument
    2.4. Collect: Data Source
    2.5. Analyze: Data Interpretation
    2.6. Formulate: Data Verification
    2.7. Publish: Research Report
    2.8. Repeat: Report Update
    3. Executive Summary
    4. Market Overview
    4.1. Introduction
    4.2. Anticonvulsants Market, by Region
    5. Market Insights
    5.1. Market Dynamics
    5.1.1. Drivers
    5.1.1.1. Growing prevalence of epilepsy among young and senior population
    5.1.1.2. Rising government initiatives supporting epilepsy awareness
    5.1.1.3. Expanding use in treating nonepileptic conditions
    5.1.2. Restraints
    5.1.2.1. Availability of substitutes options for pain management
    5.1.3. Opportunities
    5.1.3.1. Rising drug approvals of anticonvulsant drugs from regulatory bodies
    5.1.3.2. Emergence of new-generation antiepileptic drugs
    5.1.4. Challenges
    5.1.4.1. Drug supply shortage and patent expiration of the second-generation drugs
    5.2. Market Segmentation Analysis
    5.3. Market Trend Analysis
    5.4. Cumulative Impact of High Inflation
    5.5. Porter’s Five Forces Analysis
    5.5.1. Threat of New Entrants
    5.5.2. Threat of Substitutes
    5.5.3. Bargaining Power of Customers
    5.5.4. Bargaining Power of Suppliers
    5.5.5. Industry Rivalry
    5.6. Value Chain & Critical Path Analysis
    5.7. Regulatory Framework
    6. Anticonvulsants Market, by Drug types
    6.1. Introduction
    6.2. AMPA
    6.3. Barbiturate
    6.4. Benzodiazepine
    6.5. Carbamate Anticonvulsants
    6.6. Carbonic Anhydrase Inhibitor
    6.7. Dibenzazepine
    6.8. Triazine
    7. Anticonvulsants Market, by Indication
    7.1. Introduction
    7.2. Anxiety
    7.3. Bipolar Disorder
    7.4. Borderline Personality Disorder
    7.5. Epilepsy
    7.6. Fibromyalgia
    7.7. Migraine
    7.8. Neuropathic Pain
    8. Americas Anticonvulsants Market
    8.1. Introduction
    8.2. Argentina
    8.3. Brazil
    8.4. Canada
    8.5. Mexico
    8.6. United States
    9. Asia-Pacific Anticonvulsants Market
    9.1. Introduction
    9.2. Australia
    9.3. China
    9.4. India
    9.5. Indonesia
    9.6. Japan
    9.7. Malaysia
    9.8. Philippines
    9.9. Singapore
    9.10. South Korea
    9.11. Taiwan
    9.12. Thailand
    9.13. Vietnam
    10. Europe, Middle East & Africa Anticonvulsants Market
    10.1. Introduction
    10.2. Denmark
    10.3. Egypt
    10.4. Finland
    10.5. France
    10.6. Germany
    10.7. Israel
    10.8. Italy
    10.9. Netherlands
    10.10. Nigeria
    10.11. Norway
    10.12. Poland
    10.13. Qatar
    10.14. Russia
    10.15. Saudi Arabia
    10.16. South Africa
    10.17. Spain
    10.18. Sweden
    10.19. Switzerland
    10.20. Turkey
    10.21. United Arab Emirates
    10.22. United Kingdom
    11. Competitive Landscape
    11.1. FPNV Positioning Matrix
    11.2. Market Share Analysis, By Key Player
    11.3. Competitive Scenario Analysis, By Key Player
    12. Competitive Portfolio
    12.1. Key Company Profiles
    12.1.1. Abbott Laboratories
    12.1.2. Astrazeneca PLC
    12.1.3. Bausch Health Companies Inc.
    12.1.4. Biocon Limited
    12.1.5. Cadila Pharmaceuticals Limited
    12.1.6. Cipla, Inc.
    12.1.7. Dr. Reddy's Laboratories Limited
    12.1.8. Eisai Co., Ltd.
    12.1.9. GlaxoSmithKline PLC
    12.1.10. Glenmark Pharmaceuticals Ltd.
    12.1.11. Jazz Pharmaceuticals, Inc.
    12.1.12. Johnson & Johnson Services, Inc.
    12.1.13. Lifecare Neuro Products Limited
    12.1.14. Lundbeck A/S
    12.1.15. Mankind Pharma Ltd.
    12.1.16. Merck KGaA
    12.1.17. Novartis AG
    12.1.18. Novo Nordisk A/S
    12.1.19. Otsuka Pharmaceutical Co., Ltd.
    12.1.20. Pfizer Inc.
    12.1.21. Sanofi S.A.
    12.1.22. Sunovion Pharmaceuticals Inc.
    12.1.23. Takeda Pharmaceutical Company Limited
    12.1.24. Teva Pharmaceutical Industries Ltd.
    12.1.25. Wockhardt Limited
    12.2. Key Product Portfolio
    13. Appendix
    13.1. Discussion Guide
    13.2. License & Pricing
    FIGURE 1. ANTICONVULSANTS MARKET RESEARCH PROCESS
    FIGURE 2. ANTICONVULSANTS MARKET SIZE, 2023 VS 2030
    FIGURE 3. ANTICONVULSANTS MARKET SIZE, 2018-2030 (USD MILLION)
    FIGURE 4. ANTICONVULSANTS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
    FIGURE 5. ANTICONVULSANTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 6. ANTICONVULSANTS MARKET DYNAMICS
    FIGURE 7. ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2023 VS 2030 (%)
    FIGURE 8. ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 9. ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
    FIGURE 10. ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 11. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 12. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 13. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
    FIGURE 14. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 15. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 16. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 19. ANTICONVULSANTS MARKET, FPNV POSITIONING MATRIX, 2023
    FIGURE 20. ANTICONVULSANTS MARKET SHARE, BY KEY PLAYER, 2023

    Pricing

    Currency Rates
    How Do Licenses Work?

    How Do Licenses Work?

    The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

    • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

    • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

    • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

    • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

    • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

    License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

    Head shot

    Questions or Comments?

    Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
    Chat Now
    Contact Us